Publicacións en colaboración con investigadores/as de Universidade de Vigo (18)

2022

  1. Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

    Cancers, Vol. 14, Núm. 19

2021

  1. Population-based universal screening for CRC: Secondary prevention

    Foundations of Colorectal Cancer (Elsevier), pp. 45-56

  2. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities

    IUBMB Life, Vol. 73, Núm. 5, pp. 761-773

2020

  1. CD26-Related Serum Biomarkers: SCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context

    Disease Markers, Vol. 2020

2019

  1. Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets

    Biology Open, Vol. 8, Núm. 7

2018

  1. Functional assessment of the BMPR2 gene in lymphoblastoid cell lines from Graves’ disease patients

    Journal of Cellular and Molecular Medicine, Vol. 22, Núm. 3, pp. 1538-1547

2015

  1. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes

    Clinical and Experimental Immunology, Vol. 180, Núm. 2, pp. 207-217

  2. Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma

    Clinica Chimica Acta

2014

  1. Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease

    Scientific Reports, Vol. 4

  2. Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients

    PLoS ONE, Vol. 9, Núm. 9

2011

  1. Galectin-1 synthesis in type 1 diabetes by different immune cell types: Reduced synthesis by monocytes and Th1 cells

    Cellular Immunology, Vol. 271, Núm. 2, pp. 319-328

2010

  1. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

    BMC Cancer, Vol. 10

2009

  1. Soluble CD26 levels and its association to epidemiologic parameters in a sample population

    Disease Markers, Vol. 27, Núm. 6, pp. 311-316

2008

  1. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer

    Anticancer Research, Vol. 28, Núm. 4 C, pp. 2333-2341

2007

  1. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

    British Journal of Cancer, Vol. 96, Núm. 10, pp. 1569-1578

2003

  1. Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer

    Disease Markers, Vol. 19, Núm. 6, pp. 267-272

2001

  1. Cell surface human α-L-fucosidase

    European Journal of Biochemistry, Vol. 268, Núm. 11, pp. 3321-3331

2000

  1. Preoperative serum CD26 levels: Diagnostic efficiency and predictive value for colorectal cancer

    British Journal of Cancer, Vol. 83, Núm. 9, pp. 1139-1146